EXEL

Conviction 82HealthcareScan · Mon, Aug 10, 2026

EXEL$52.97-2.03%

ResistanceSupportVol 14Insider sell

Vol MA14 3.02M

May 11May 28Jun 16Jul 6Jul 23Aug 10

EXELIXIS, INC.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.exelixis.com ↗

Price52.97

Change-2.03%

Gap-1.11%

Rel volume1.80×

Avg volume2.74M

Avg $ vol150.49M

SMA 2055.21

SMA 5054.08

SMA 20046.28

Price vs 50-2.06%

Price vs 200+14.45%

MA stackmixed

50/200 cross—

Supertrendup · 51.96

RSI (14)45

MACD hist-0.41

MACD cross—

Stoch %K / %D23 / 25

ADX (14)22

+DI / −DI14 / 26

RSI divergenceBearish

MACD divergence—

ATR %+3.60%

ADR %3.12%

52w high57.10

52w low34.54

From 52w high-7.23%

Above 52w low+53.36%

New 52w highNo

SqueezeFired

Bollinger width8.57%

%B0.03

Donchian pos23.33%

Donchian high56.95

Donchian low51.76

AVWAP (52w high)55.23

vs AVWAP high-4.08%

AVWAP (52w low)45.86

vs AVWAP low+15.50%

OBV trendFlat

Chaikin MF (20)0.07

Today vs 20d1.80×

Avg vol (14d)3.02M

Avg vol (20d)2.74M

Avg $ vol (20d)150.49M

Market cap—

RS 3m (vs SPY)+11.31%

RS 6m (vs SPY)+13.50%

RS line new highNo

Trend template7/8

Technical rank56.4

1 week-3.80%

1 month-6.25%

3 months+9.99%

6 months+20.66%

1 year+41.67%

YTD+21.55%

P/E17.12

P/B7.27

P/S5.78

P/FCF15.30

EPS2.78

Div yield—

ROE42.44%

ROA31.38%

Debt/Eq0.10

Current3.46

EV/EBITDA14.77

Gross margin8.25%

Net margin33.73%

Rev growth6.98%

EPS growth50.13%

Price target51.75

Target upside-4.31%

Analyst ratingHold

Institutional116.04%

Ent. value13.31B

Revenue628.69M

Net income212.05M

Gross profit—

Free cash flow875.84M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out251.36M

Employees1.08K

ListedTue, Apr 11, 2000

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA

Conviction82 / 100

Pattern quality—

Tech rank56.4 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance57.26

Support51.28

Days since event—

Candle confirm—

News sentiment—

Financials as of Fri, Jul 3, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in EXEL

All disclosures →

No recent disclosed trades by Congress in EXEL. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in EXEL · 8 buys · 2 sells

Insider	Side	Shares	Value	Traded	Filed
WYSZOMIERSKI JACK L Director · Common Stock · 2026-06-01	Sell	3.92K	$198K	2026-06-01	2026-06-03
Eckhardt Sue Gail Director · Common Stock · 2026-06-01	Sell	9.81K	$492K	2026-06-01	2026-06-03
Smith Julie Director · Common Stock · 2026-05-27	Grant	8.37K	$0	2026-05-27	2026-05-29
PAPADOPOULOS STELIOS Director · Common Stock · 2026-05-27	Grant	8.37K	$0	2026-05-27	2026-05-29
POSTE GEORGE Director · Common Stock · 2026-05-27	Grant	8.37K	$0	2026-05-27	2026-05-29
JOHNSON DAVID EDWARD Director · Option (right to buy) · 2026-05-27	Grant	19.13K	$0	2026-05-27	2026-05-29
Eckhardt Sue Gail Director · Common Stock · 2026-05-27	Grant	8.37K	$0	2026-05-27	2026-05-29
Freire Maria C Director · Common Stock · 2026-05-27	Grant	8.37K	$0	2026-05-27	2026-05-29
Oliver Bob Director · Common Stock · 2026-05-27	Grant	8.37K	$0	2026-05-27	2026-05-29
Heyman Tomas J. Director · Common Stock · 2026-05-27	Grant	8.37K	$0	2026-05-27	2026-05-29

SEC filings

EDGAR filings in EXEL · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.